Lumos Pharma, Inc.
NASDAQ:LUMO
3.92 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2.051 | 1.523 | 0.23 | 0.168 | 0.936 | 1.206 | 0.39 | 3.526 | 36.143 | 165.95 | 1.093 | 1.687 | 1.872 | 2.079 | 0.934 | 0.633 |
| Cost of Revenue
| 0.044 | 0.049 | 0 | 0 | 0.037 | -11.268 | 1.407 | 0 | -32.358 | -6.642 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 2.007 | 1.474 | 0.23 | 0.168 | 0.899 | 12.474 | -1.017 | 3.526 | 68.501 | 172.592 | 1.093 | 1.687 | 1.872 | 2.079 | 0.934 | 0.633 |
| Gross Profit Ratio
| 0.979 | 0.968 | 1 | 1 | 0.96 | 10.343 | -2.608 | 1 | 1.895 | 1.04 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 22.096 | 17.857 | 16.246 | 9.206 | 22.205 | 45.694 | 69.866 | 93.3 | 71.414 | 35.691 | 22.713 | 17.838 | 14.255 | 12.666 | 5.559 | 5.451 |
| General & Administrative Expenses
| 16.569 | 15.706 | 15.331 | 17.265 | 23.865 | 29.218 | 31.726 | 33.226 | 30.689 | 19.328 | 9.521 | 7.108 | 5.679 | 6.074 | 5.192 | 4.597 |
| Selling & Marketing Expenses
| -0.044 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 16.525 | 15.706 | 15.331 | 17.265 | 23.865 | 29.218 | 31.726 | 33.226 | 30.689 | 19.328 | 9.521 | 7.108 | 5.679 | 6.074 | 5.192 | 4.597 |
| Other Expenses
| 0.683 | 0.091 | 0.269 | 6.467 | -0.019 | -0.102 | 0.371 | 0.247 | -0.041 | 0.06 | 0.091 | -0.062 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 38.621 | 33.563 | 31.577 | 26.471 | 46.07 | 63.644 | 73.271 | 94.284 | 69.745 | 48.377 | 31.141 | 23.259 | 19.934 | 18.74 | 10.751 | 10.048 |
| Operating Income
| -36.614 | -32.04 | -31.347 | -26.303 | -45.134 | -62.438 | -72.881 | -90.758 | -33.602 | 117.573 | -31.141 | -23.259 | -18.062 | -16.661 | -9.817 | -9.415 |
| Operating Income Ratio
| -17.852 | -21.037 | -136.291 | -156.565 | -48.22 | -51.773 | -186.874 | -25.74 | -0.93 | 0.708 | -28.491 | -13.787 | -9.649 | -8.014 | -10.511 | -14.874 |
| Total Other Income Expenses Net
| 2.551 | 0.965 | 0.281 | 6.667 | 2.157 | -0.102 | 0.371 | 0.247 | -0.041 | 0.06 | 0.091 | -0.062 | 0.005 | 0.071 | 0.019 | 0.042 |
| Income Before Tax
| -34.063 | -31.075 | -31.066 | -19.636 | -42.977 | -60.563 | -72.51 | -90.511 | -33.643 | 117.633 | -31.05 | -23.321 | -18.088 | -16.59 | -9.798 | -9.373 |
| Income Before Tax Ratio
| -16.608 | -20.404 | -135.07 | -116.881 | -45.916 | -50.218 | -185.923 | -25.67 | -0.931 | 0.709 | -28.408 | -13.824 | -9.662 | -7.98 | -10.49 | -14.807 |
| Income Tax Expense
| -0.029 | -0.013 | -0.636 | -13.973 | 0.012 | -6.968 | -0.559 | -5.356 | 6.738 | 14.775 | 0.13 | -0.788 | 0.041 | -0.448 | -0.375 | -0.253 |
| Net Income
| -34.034 | -31.062 | -30.43 | -5.663 | -42.989 | -53.595 | -71.951 | -85.155 | -40.381 | 102.858 | -31.18 | -23.321 | -18.087 | -16.213 | -9.442 | -9.162 |
| Net Income Ratio
| -16.594 | -20.395 | -132.304 | -33.708 | -45.928 | -44.44 | -184.49 | -24.151 | -1.117 | 0.62 | -28.527 | -13.824 | -9.662 | -7.798 | -10.109 | -14.474 |
| EPS
| -4.18 | -3.71 | -3.65 | -0.84 | -297.07 | -12.97 | -20.69 | -26.45 | -12.71 | 31.05 | -11.1 | -10.1 | -26.84 | -10.15 | -5.91 | -5.74 |
| EPS Diluted
| -4.18 | -3.71 | -3.65 | -0.84 | -297.07 | -12.97 | -20.69 | -26.45 | -12.71 | 27.81 | -11.1 | -10.1 | -26.84 | -10.15 | -5.91 | -5.74 |
| EBITDA
| -36.57 | -32.04 | -31.347 | -26.303 | -42.927 | -60.511 | -72.881 | -90.758 | -33.602 | 117.573 | -31.141 | -23.259 | -17.364 | -16.077 | -9.533 | -9.163 |
| EBITDA Ratio
| -17.83 | -21.037 | -136.291 | -156.565 | -45.862 | -50.175 | -186.874 | -25.74 | -0.93 | 0.708 | -28.491 | -13.787 | -9.276 | -7.733 | -10.207 | -14.476 |